Showcase

公司名稱 Company Name

思諾達生物醫藥有限公司
Sinotar BioPharm Limited
公司簡介 Company Background
思諾達生物醫藥有限公司是一家以創新為核心驅動力的腫瘤創新藥研發公司，以精准醫療為理念，以 “打造全球領先的原創抗腫瘤藥物” 為發展目標，深度融合前沿組學、AI、類器官技術，依託頂尖跨學科研發團隊、自主構建三大核心技術體系，深耕腫瘤領域，致力於為臨床提供更高效、更安全、更具普適性的腫瘤治療方案。
Sinotar Biopharmaceutical Ltd. is an innovation‑driven biotech company focused on the discovery and development of novel oncology drugs. Guided by precision medicine, we aim to create globally competitive original anti‑cancer therapies. We deeply integrate cutting-edge omics, artificial intelligence, and organoid technologies. Backed by a world-class interdisciplinary R&D team and three proprietary core technology platforms, we are committed to delivering more effective, safer, and broadly applicable cancer treatment solutions for clinical use.
陳列產品之簡介 Description of displayed product
SIN001是全球首個靶向BAD磷酸化位點的1.1類原創抗腫瘤新藥，本品通過阻斷BAD磷酸化、重啟腫瘤細胞凋亡通路，精准殺傷癌細胞，攻克多重激酶抑制劑耐藥問題，兼具靶向性強、副作用小的優勢，可有效治療乳腺癌、肺癌、卵巢癌等多種實體瘤，還能聯合用藥協同性強，填補耐藥腫瘤臨床治療領域空白。
SIN001 is the world’s first Class 1.1 anti-cancer drug targeting the BAD (Ser99) phosphorylation site. It directly blocks BAD phosphorylation, restores apoptosis, and overcomes drug resistance associated with multiple kinase inhibitors. It shows potent activity against breast, lung, ovarian, colorectal, and endometrial cancers. Supported by a world-leading interdisciplinary team, SIN001 features high specificity, low side effects, and strong synergy with other therapies. It is expected to become a first-in-class core drug for solid tumors and address unmet clinical needs in drug-resistant cancers.
公司產品 Company products